- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Volume is elevated versus the 13-week average, confirming attention.
- Next-week expectancy is positive at 58.27% based on similar historical setup states.
2630
HKG
Week ended 07 Aug 2026
Weekly Investor Report
Vigonvita Life Sciences Co., Ltd. · Healthcare · Drug Manufacturers - General
Latest close
116.8 HKD
22.8%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 35.3% above the Trend Line and sits at 78.4% of its 52-week range. The latest completed week returned 22.8%, after a 116.3% four-week move. The latest news-sentiment score is 50/100.
Setup score
50
out of 100
Latest Close
116.8 HKD
7 Aug 2026
1W Return
22.8%
latest completed week
4W Return
116.3%
short-term follow-through
12W Return
46.1%
quarterly tape
Trend Breadth
0.0%
0 of 40 weeks active
Volume Ratio
2.1x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
22.8%
Latest completed week; four-week move 116.3%.
Indicator stack
0/47
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Positive 58.27%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
3 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 35.3% above the Trend Line and sits at 78.4% of its 52-week range. The latest completed week returned 22.8%, after a 116.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.1x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0912-week average 0.09
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.09Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 116.3% over four weeks, 46.1% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.47Latest activity-pressure read.
Pressure change73.4%Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 3 relevant articles.
0 positive · 3 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-13.4%Distance below the 52-week high.
13-week volatility14.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+37.8%Week of 24 Jul.
Worst week-30.9%Week of 27 Mar.
Latest week+22.8%Week of 7 Aug.
Shape of recent returns
Strong gains10
Modest gains3
Flat weeks0
Modest losses4
Sharp losses9
Recent vol14.2%13-week weekly-return volatility.
Base vol11.8%52-week weekly-return volatility.
Up/down split23/16Count of positive and negative weeks in the 52-week window.
Average skew9.5% / -8.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorHK Healthcare
4-week rank1 / 100
Group average4.4%
Trend breadth12.0%
Trend12.0%active weekly trend signals
MD32.0%positive activity pressure
RS19.0%positive relative leadership
Four-week leaders
IndustryHK Drug Manufacturers - General
4-week rank1 / 7
Group average28.5%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD28.6%positive activity pressure
RS0.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape40/100
Trend, activity pressure, participation, and risk combine to a 40/100 tape read.
Indicator analysis10/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.09; No reversal markers Next-Week ExpectancyPositive 58.27%Next-week expectancy is positive with a 58.27% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 3 relevant articles.
Deloitte China assists listings of Pony AI and Vigonvita Life Sciences on SEHK Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 116.8 HKD | 22.8% | 86.30 HKD | 83.48 HKD | -0.47 | - | 450.6K | Off |
| 31 Jul 2026 | 95.15 HKD | 22.0% | 85.23 HKD | 82.63 HKD | -0.88 | - | 529.0K | Off |
| 24 Jul 2026 | 78.00 HKD | 37.8% | 84.86 HKD | 82.30 HKD | -1.36 | - | 468.9K | Off |
| 17 Jul 2026 | 56.60 HKD | 4.8% | 85.08 HKD | 82.42 HKD | -1.73 | - | 228.6K | Off |
| 10 Jul 2026 | 54.00 HKD | -8.1% | 85.93 HKD | 83.13 HKD | -1.76 | - | 182.4K | Off |
| 3 Jul 2026 | 58.75 HKD | -0.4% | 86.58 HKD | 83.97 HKD | -1.73 | - | 34.8K | Off |
| 26 Jun 2026 | 59.00 HKD | 0.8% | 87.19 HKD | 84.71 HKD | -1.59 | - | 27.0K | Off |
| 19 Jun 2026 | 58.55 HKD | -3.7% | 87.56 HKD | 85.49 HKD | -1.39 | - | 127.6K | Off |
| 12 Jun 2026 | 60.80 HKD | -7.2% | 87.61 HKD | 86.33 HKD | -1.18 | - | 31.4K | Off |
| 5 Jun 2026 | 65.50 HKD | -13.2% | 87.85 HKD | 87.15 HKD | -1.06 | - | 27.4K | Off |
| 29 May 2026 | 75.45 HKD | -7.5% | 87.87 HKD | 87.87 HKD | -0.96 | - | 157.2K | Off |
| 22 May 2026 | 81.60 HKD | 2.1% | - | 88.30 HKD | -0.68 | - | 266.2K | Off |
| 15 May 2026 | 79.95 HKD | 3.4% | - | 88.54 HKD | - | - | 222.6K | Off |
| 8 May 2026 | 77.30 HKD | 7.7% | - | 88.86 HKD | - | - | 173.2K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.